Authors : Priyadarshini M. Chaudhary; Dr. Khushbu K. Patel; Dr. C. N. Patel

Volume/Issue : Volume 11 - 2026, Issue 1 - January

Google Scholar : https://tinyurl.com/2dvjvuxs

Scribd : https://tinyurl.com/3mzw3z65

DOI : https://doi.org/10.38124/ijisrt/26jan731

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Diabetes mellitus (DM) is a chronic metabolic disorder characterized by elevated blood glucose levels resulting from defects in insulin secretion, insulin action, or both. Persistent hyperglycemia in diabetes leads to disturbances in carbohydrate, fat, and protein metabolism. It is mainly classified into type I and type II DM. Type I Diabetes Mellitus (DM) is primarily managed through insulin replacement therapy, as pancreatic β-cell destruction results in absolute insulin deficiency. In contrast, Type II DM is typically treated with oral hypoglycaemic agents and, when necessary, insulin therapy. Combination therapy is often employed to achieve optimal glycaemic control and minimize complications. Globally, Diabetes Mellitus represents a major public health challenge, with an estimated 589 million adults projected to be affected by 2025, reflecting the increasing prevalence linked to sedentary lifestyles, obesity, and aging populations.

Keywords : Molnupiravir, Diabetes Mellitus, Development and Validation, RP-HPLC.

References :

1. V. Singh, “An Overview of Anti Diabetic Drugs and Development,” Sci. and Tech. J. vol. 4(2), pp. 113-123, July 2016.
2. Priyadarshini Chaudhari, Mayur Prajapati, Nidhi Patel, Dhruv Patel, Anjali Prajapati, and Khushbu Patel. “Newer Approaches for Analytical Method Validation of Anti Diabetic Agents: A Review,” Int. J. of Inno. Sci. and Res. Tech. 9(12), pp. 650-669, July 2024.
3. R.A. DeFronzo, “From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus Diabetes,” PMCID, Banting Lecture, April 2009.
4. Priyadarshini Chaudhari, Mona Gupta, Dr. Khushbu Patel, Dr. C. N. Patel. “Detail review on pharmacokinetic parameters, efficacy and safety of Ertugliflozin,” Int. J. of Pharma. Sci. 2(12), pp. 2409-2419, 2024.
5. Khushbu Patel, C. N. Patel, Henee Patel. “QbD based RP-HPLC Method Development and Validation for Estimation of Evogliptin Tartrate in Pharmaceutical Dosage Form,” Int. J. of Pharma. Sci. and Nano. 17(6), pp. 7688-7696, 2025.
6. R. Khursheed, S.K. Singh, S. Wadhwa, B. Kapoor, M. Gulati, R. Kumar, A.K. Ramanunny, A. Awasthi, K. Dua, "Treatment strategies against diabetes: Success so far and challenges ahead," Eur. J. Pharmacol. vol. 5, pp. 862, Nov 2019.
7. Priyadarshini Chaudhari, Mayur Prajapati, Jaimin Suthar, Vishvesh Panchal, Khushbu Patel, C. N. Patel. “Spectrophotometric Method Development and Validation for Simultaneous Estimation of Metformin Hydrochloride and Evogliptin Tartrate in Pharmaceutical Dosage Form,” Asi. J. of Pharma. Anal. 15(1), pp. 45-50, 2025;.
8. Patel K, Shah UA, Joshi HV, Patel JK, Patel CN. “QbD Stressed development and validation of stability-indicating RP-HPLC method for the simultaneous estimation of linagliptin and metformin HCl in pharmaceutical dosage form,” Res. J. of Pharm. Tech. 15(5), pp. 1917-23, 2022.
9. P. Chaudhari, M. Prajapari, J. Suthar, K. Patel, C.N. Patel, "Review on Analytical Method Development and Validation for Evogliptin Tartrate and Metformin Hydrochloride," Int. J. of Phar. and Pharma. Res. vol. 30(1), pp. 340-357, Feb 2024
10. Drugbank, “Drug Profile of Metformin Hydrochloride,” Jan 2026. https://go.drugbank.com/drugs/DB00331
11. Drugbank, “Dapagliflozin,” Jan 2026. https://go.drugbank.com/drugs/DB06292
12. Harshil R. Thakkar, Mohammadarsh B. Mansuri, Dr. Khushbu Patel, Dr. C. N. Patel. “Dapagliflozin Analysis: A Review on Chromatography and Spectroscopic Methods,” Int. J. of Inno. Sci. and Res. Tech. 10(1), pp. 1985-1996, 2025.
13. ClinPG, “Glimepiride,” Jan 2026. https://www.clinpgx.org/chemical/PA449761
14. K. Trerattanavong, P. Tadi, “Glimepiride,” Nat. Lib. of Med. July 2023
15. Drugbank, “Glimepiride”, Jan 2026. https://go.drugbank.com/drugs/DB00222
16. The Indian Pharmacopoeia, Government of India, “Ministry of Health and Family Welfare,” The Indian Pharmacopeia Commission. Ghaziabad, 9^th Edition, pp. 2874-2875, 2022-II.
17. The Indian Pharmacopoeia, Government of India, “Ministry of Health and Family Welfare,” The Indian Pharmacopeia Commission. Ghaziabad, 9^th Edition, pp. 2878, 2022-II.
18. The Indian Pharmacopoeia, Government of India, “Ministry of Health and Family Welfare,” The Indian Pharmacopeia Commission. Ghaziabad, 9^th Edition, pp. 2477, 2022-II.
19. The Indian Pharmacopoeia, Government of India, “Ministry of Health and Family Welfare,” The Indian Pharmacopeia Commission. Ghaziabad, 9^th Edition, pp. 2478, 2022-II.
20. Y.D. Dange, S.M. Honmane1, S.D.Bhinge, V.R. Salunkhe, D.R. Jadge, “Development and Validation of UV-Spectrophotometric Method for Estimation of Metformin in Bulk and Tablet Dosage Form,” Ind. J. of Pharma. Edu. and Res. vol. 51(4S), pp. S745-S760, Oct 2017.
21. A.R. Rote, R.B. Saudagar, “Estimation of Metformin Hydrochloride by UV Spectrophotometric Method in Pharmaceutical Formulation,” Wor. J. of Pharma. Sci. vol. 2(12), pp. 1841-1845, Nov 2014.
22. M. Kar, P.K. Choudhury, “HPLC Method for Estimation of Metformin Hydrochloride in Formulated Microspheres and Tablet Dosage Form,” Ind. J. Pharma. Sci. vol. 71(3), pp. 318-320, May 2009.
23. M. Sha’at, A.F. Spac, I. Stoleriu, A.Bujor, M.S. Cretan, M. Hartan, L. Ochiuz, “Implementation of QbD Approach to the Analytical Method Development and Validation for the Estimation of Metformin Hydrochloride in Tablet Dosage Form by HPLC,” Pharma. vol. 14(6), pp. 1187, May 2022.
24. C.H.M. Reddy, G. Mubeen, M. Pal, “HPTLC Method for Estimation of Metformin Hydrochloride,” Bio. and Pharma. J. vol. 1(2), pp. 505, Oct 2008.
25. P. Jain, D. Girase, A. Bedse, S. Surana, “Stability- Indicating HPTLC Densitometric Method for Determination of Metformin Hydrochloride in Tablet Formulation,” J. of Pharma. and Bio. vol. 1, pp. 51-58, June 2013   .
26. G.V. Mante, K.R. Gupta, A.T. Hemke, “Estimation of Dapagliflozin from its Tablet Formulation by UV-Spectrophotometry,” Pharma. Meth. vol. 8(2), pp. 102-107, July 2017.
27. S. Vadla, V. Putta, S. Nadipudi, S. Bilakanti, N. Kudumula, “Estimation Method for Dapagliflozin in Bulk and Marketed Dosage Form: Development and Validation by UV-Spectroscopy,” Int. J. of Pharma. and Phyto. Res. vol. 13(4), pp. 1-6, Aug 2023.
28. D.C. Kavana, N.S. Kumar, “A Novel UV Spectrophotometric Method Development and Validation of Dapagliflozin in Bulk and Pharmaceutical Dosage Form,” Wor. J. of Pharma. Res. vol. 14(13), pp. 1365-1373, June 2025.
29. M.V. Verma, C.J. Patel, M.M Patel, “Development and Stability Indicating HPLC Method for Dapagliflozin in API and Pharmaceutical Dosage Form,” Int. J. of App. Pharma. vol. 9(5), pp. 33-37, Sep 2017.
30. K.B. Bodiwala, J. Shah, D.K. Sureja, T.M. Dhameliya, A. Khadela, “Generation of Predictive Models for Oxidative Degradation Kinetics of Dapagliflozin with the Applications of DOE and Stability Indicating HPLC Method,” Int. J. of Chem. Kin. vol. 54(12), pp. 712-725, Sep 2022.
31. J. Debata, S. Kumar, S. Jha, A. Khan, “A New RP-HPLC Method Development and Validation of Dapagliflozin in Bulk and Tablet Dosage Form,” Int. J. of Drug Deve. and Res. vol. 9(2), pp. 48-51, June 2017.
32. S. Venkatapa, D. Raja, P. Shenoy, “A New High-Performance Thin Layer Chromatographic Method Development and Validation of Dapagliflozin in Bulk and Tablet Dosage Form,” Int. J. of Pharm. and Pharma. Sci. vol. 11(8), pp. 58-63, July 2019.
33. B. Sakala, S. Gopisetty, K. Dantu, S. Kota, “UV Spectrophotometric Method for Determination of Glimepiride in Pharmaceutical Dosage Forms,” Int. J. Pharm. Sci. Rev. Res. vol. 21(2), pp. 131-133, Aug 2014.
34. R. Bonfilio, M.B. de Araujo, H. Salgado, “Development and Validation of an UV-Derivative Spectrophotometric Method for Determination of Glimepiride in Tablets,” J. of Braz. Chem. Soc. vol. 22(2), pp. 103-110, Feb 2011.
35. Dr. S. Naveed, H. Qamar, W. Jawaid, U. Bokhari, “Simple UV Spectrophotometric Assay of Glimepiride,” Ope. Sci. J. of Clin. Medi. vol. 2(4), pp. 94-97, Oct 2014.
36. I.U. Khan, F. Aslam, M. Ashfaq, M.N. Asghar, “Determination of Glimepiride in Pharmaceutical Formulations using HPLC and First- Derivative Spectrophotometric Methods,” J. of Analy. Chem. vol. 64, pp.171-175, Feb 2009.
37. A. Kumar, C. Dhiman, M. Kumar, N. Kannappan, “Development of a quality by design based hybrid RP-HPLC method for Glimepiride: Bioanalytical and industrial applications,” J. of Appl. Pharma. Sci. vol. 15(4), pp. 102–115, Jan 2025.
38. D. Pokharkar, Dr. C.K. Tyagi, “Stress Stability Study Showing Effect of Acid, Base, H₂O₂ and Dry Heat on Glimepiride by HPTLC Method,” Wor. J. of Pharma. Res. vol. 10(7), pp. 804-813, June 2021.
39. D.S. Nandre, A. Ahmed, G.J. Khan, “Stability indicating HPLC Method Development and Validation for Simultaneous Estimation of Dapagliflozin and Metformin Tablet Dosage Form,” Asi. J. of Pharma. And Clin. Res. vol. 15(10), pp. 109-114, Oct 2022.
40. W. Siddique, Z. Ahmed, H. Umar, S.J. Usmani, “Method Development and Validation of Metformin HCl. and Dapagliflozin by using RP-HPLC,” Acta. Chroma. vol. 37(2), pp. 176-182, July 2024.
41. A.D. Patil, V.D. Patil, Dr. R. Yamgar, Dr. R. Gavande, J. Patil, “An improved validated RP-HPLC method for the simultaneous estimation of Metformin and Dapagliflozin,” Int. J. of Food and Nutri. Sci. vol. 12(1), pp. 4313-4323, May 2023.
42. L. Rayudu, Dr. M.P. Rao, C. Mannempali, D.N. Rao, K.N. Harini, “RP-HPLC Method Development and Validation of Metformin Hydrochloride & Glimepiride in Fixed Dose Combination and Evaluation of 5 Marketed Formulations by Quality by Design,” Wor. J. of Pharma. Res. vol. 2(6), pp. 523-531, July 2024.
43. Dr. M. Charde, “Validated RP-HPLC Method Development for the Simultaneous Estimation of Metformin and Glimepiride in Combine Tablet Dosage Form,” Int. J. of Phyto. vol. 5(6), pp. 114-126, June 2016.